As we move through 2026, the global focus on supportive oncology has reached an all-time high. Radiodermatitis, a skin condition affecting approximately 95% of patients undergoing radiation therapy, is no longer viewed as a secondary concern but as a primary clinical priority. According to the latest Radiodermatitis market growth, the industry is expanding at a steady CAGR of approximately...

The Radiodermatitis Market is witnessing a remarkable rise in volume due to the innovative treatment options being developed to address the complications arising from cancer therapies. As the market is projected to reach USD 3.132 billion by 2035, the growth is driven by both an increased incidence of cancer and a heightened awareness among patients regarding treatment options. Notably, the...